Multidrug Antifungal Resistance and Clinical Outcomes in Fungal Keratitis: A Prospective Study in a South Indian Population

A prospective study of fungal keratitis patients in South India revealed high rates of multidrug resistance, particularly among *Fusarium* and *Aspergillus* isolates, with natamycin resistance significantly correlating with poorer clinical outcomes and underscoring the need for species-specific treatment thresholds.

The Gist

Imagine your eye is like a beautiful, clear window. Now, imagine a tiny, invisible invader—a fungus—trying to break that window. This condition is called Fungal Keratitis. It's a serious infection that can lead to blindness, and it's a huge problem in rural parts of India, often caused by dirt or plant matter getting into the eye after an injury.

Doctors usually treat this by painting the eye with special "fungus-killing" drops (antifungals). Think of these drops as different types of superheroes designed to fight specific villains. The main superheroes in this story are:

• Natamycin (The classic shield)
• Amphotericin B (The heavy artillery)
• Voriconazole and Econazole (The modern wizards)

This study, conducted by researchers in South India, asked a scary question: "Are the villains getting too strong for our superheroes?"

Here is the story of what they found, broken down simply:

1. The Villains Are Wearing "Super-Suits" (Resistance)

The researchers collected samples from 153 patients. They took the fungi out of the patients' eyes and tested them in a lab against the four main superhero drugs.

The results were alarming. It's like the villains had put on bulletproof vests.

• The Fusarium Gang: This is a very common type of fungus. In this study, almost all of them (97%) were immune to the "wizard" drug (Voriconazole), and nearly all (94%) were immune to the "heavy artillery" (Amphotericin B). Even the "classic shield" (Natamycin) only worked on about 60% of them.
• The Aspergillus Gang: This group was also tough. They were immune to the heavy artillery (88%) and the classic shield (67%). However, they were still vulnerable to the "wizard" drugs.

The Big Takeaway: Most of these fungi were Multidrug Resistant. This means they could shrug off multiple types of attacks. In fact, about 15% of the Fusarium bacteria were so tough that none of the four drugs could kill them in the lab.

2. Where Did They Get So Strong? (The Farm Connection)

You might think, "Did these people use too much medicine, making the bugs resistant?"
Surprisingly, no. Most patients had never used these specific eye drops before getting sick.

So, where did the resistance come from? The researchers suspect the environment.

• The Analogy: Imagine farmers spraying crops with fungicides (chemicals that kill fungi) to protect their harvest. Over time, the fungi in the soil and on the plants evolve to survive those chemicals.
• When a farmer gets a scratch from a plant, they aren't just getting a random fungus; they are getting a veteran soldier that has already learned how to survive chemical attacks. This is why the fungi in the eye are so strong—they learned their tricks in the fields, not in the hospital.

3. The Consequences: When the Shield Fails

The study also looked at what happened to the patients.

• If the fungus was resistant to Natamycin (the most common first-line treatment), the patient was much more likely to have a bad outcome.
• The Metaphor: Imagine trying to put out a fire with a water hose that has a hole in it. If the fire (the fungus) is resistant to the water (the drug), the fire keeps burning. In severe cases, the "window" (the cornea) gets so damaged that it needs to be replaced entirely (a corneal transplant).

Interestingly, this was especially true for the Aspergillus group. Even though they were vulnerable to the "wizard" drugs, if they were resistant to the "classic shield" (Natamycin), the infection was harder to control.

4. Why This Matters

This study is like a warning siren.

• Old Maps Don't Work: The rules doctors use to decide which drug to give (based on studies from the UK or US) might not work in South India. The "villains" there are different and tougher.
• We Need New Weapons: We are running out of effective drugs. If the fungi keep getting stronger, we might reach a point where we have no way to treat these infections without removing the eye.
• One Health Approach: The study suggests we need to look at the whole picture—farming, the environment, and human health together. If we stop overusing chemicals on crops, maybe we can stop creating these "super-fungi."

In a Nutshell

The researchers found that fungal eye infections in South India are becoming incredibly hard to treat because the fungi are evolving to resist our best medicines, likely due to their exposure to farm chemicals. This makes the infections more dangerous and harder to cure. The study is a call to action: we need better local testing, smarter farming practices, and new treatments before we run out of ways to save people's sight.

Technical Summary

1. Problem Statement

Fungal keratitis (FK) is a leading cause of visual impairment and blindness globally, particularly in tropical rural populations. Treatment is challenging due to a limited arsenal of antifungal drugs (primarily polyenes like natamycin and amphotericin B, and azoles like voriconazole and econazole).

• Knowledge Gap: Antifungal susceptibility testing (AST) is rarely performed routinely, leaving the true scale of antifungal resistance (AFR) and multidrug resistance (MDR) poorly understood.
• Clinical Uncertainty: There is a lack of data correlating in vitro Minimum Inhibitory Concentration (MIC) values with actual clinical patient outcomes.
• Regional Disparity: Global resistance patterns vary significantly, yet most guidelines rely on data that may not reflect local epidemiological realities, particularly in South India where agricultural exposure is high.

2. Methodology

• Study Design: Prospective observational study conducted at Aravind Eye Hospital, Madurai, India.
• Population: 153 consecutive patients with culture-positive fungal keratitis enrolled between May and August 2025.
• Data Collection:
  • Clinical: Visual acuity, ulcer characteristics (size, depth, severity), and treatment history were recorded at baseline, 1 week, and 1 month.
  • Microbiology: Corneal scrapings were cultured on blood and potato dextrose agar. Isolates were identified to genus/species level via morphology.
• Susceptibility Testing:
  • Method: Broth microdilution following CLSI M38-A3 guidelines.
  • Agents Tested: Natamycin, Amphotericin B, Voriconazole, and Econazole.
  • Breakpoints (CLSI): Natamycin (≥8.0 µg/mL), Amphotericin B (≥2.0 µg/mL), Voriconazole (≥2.0 µg/mL), Econazole (≥8.0 µg/mL).
• Statistical Analysis:
  • MIC comparisons across genera used Kruskal-Wallis with Dunn's test.
  • Correlation between MIC and clinical measures used Spearman's rank correlation.
  • Association between resistance and clinical outcome (healed vs. poor outcome/therapeutic penetrating keratoplasty) used Fisher's exact test.

3. Key Results

A. Resistance Profiles

• Overall Resistance: High levels of resistance were observed across all four drug classes:
  • Natamycin: 35.8%
  • Amphotericin B: 74.8%
  • Voriconazole: 58.3%
  • Econazole: 41.7%
• Genus-Specific Patterns:
  • Fusarium spp. (n=81): Exhibited extreme multidrug resistance.
    • Natamycin: 38.3%
    • Amphotericin B: 93.8%
    • Voriconazole: 97.5%
    • Econazole: 76.5%
    • Critical Finding: 15.2% of Fusarium isolates were resistant to all four drugs. None were susceptible to all four.
  • Aspergillus spp. (n=33): Showed high resistance to polyenes but lower resistance to azoles.
    • Natamycin: 66.7%
    • Amphotericin B: 87.9%
    • Voriconazole: 6.1%
    • Econazole: 0%
• Multidrug Resistance (MDR): 66.9% of all isolates were resistant to more than one antifungal. Only 27 isolates were susceptible to all four drugs (none were Fusarium).

B. Risk Factors and Prior Exposure

• Prior Treatment: 48% of patients had used topical medication prior to enrollment.
• Resistance vs. History: The majority of patients with resistant strains had no history of using the specific antifungal to which they were resistant (e.g., 99.1% of Amphotericin B-resistant cases had no prior Amphotericin B use).
• Implication: This suggests environmental selection pressure (likely agricultural fungicide use) rather than direct clinical overuse is driving resistance in this population.

C. Clinical Outcomes

• Follow-up: 91 patients (59.5%) had known outcomes; 32 had poor outcomes (requiring therapeutic penetrating keratoplasty).
• Natamycin Resistance Impact:
  • Natamycin resistance significantly correlated with poor clinical outcomes (P=0.0034).
  • Relative Risk: 1.7 (95% CI: 1.2–2.6).
  • Attributable Risk: 31% increase in poor outcomes.
  • Genus Specificity: This correlation was significant for Aspergillus spp. (P=0.0251) but not for Fusarium spp. (likely due to the near-universal resistance of Fusarium to all drugs).
• Correlations: Higher natamycin MICs correlated with worse ulcer severity scores at baseline and longer delays in seeking healthcare.

4. Key Contributions

1. First Regional MDR Profile: Provides the first comprehensive data on multidrug resistance patterns specifically for South Indian fungal keratitis isolates, revealing resistance rates significantly higher than those reported in the UK.
2. Clinical Correlation: Establishes a statistically significant link between in vitro natamycin resistance and poor clinical outcomes (specifically the need for corneal transplantation), validating the clinical utility of susceptibility testing.
3. Environmental Hypothesis: Highlights that resistance is likely driven by environmental agricultural practices (One Health approach) rather than just clinical misuse, given the lack of prior drug exposure in most resistant cases.
4. Species-Specific Nuance: Demonstrates that resistance patterns are highly genus-dependent (e.g., Fusarium is pan-resistant, while Aspergillus remains susceptible to azoles but resistant to polyenes).

5. Significance and Implications

• Treatment Guidelines: Current "one-size-fits-all" guidelines are insufficient. The data supports the need for species-specific MIC thresholds and empiric treatment protocols tailored to local resistance patterns.
• Stewardship: The high rate of resistance to first-line agents (natamycin) and the prevalence of MDR suggest that standard empiric therapy may fail frequently in this region, necessitating earlier susceptibility testing.
• Public Health: The disconnect between patient drug history and resistance profiles underscores the critical role of agricultural fungicide use in driving human fungal infections, calling for a "One Health" surveillance strategy.
• Future Research: The study highlights the urgent need for standardized, clinically relevant MIC breakpoints for topical antifungal therapy, as current systemic breakpoints may not accurately predict topical treatment success, especially in biofilm-associated infections.